Efficacy and Safety of Levofloxacin in the Context of Other Contemporary Fluoroquinolones: A Review

Current Therapeutic Research - Clinical and Experimental

Volumn 64, Issue 9, 2003, Pages 646-661

  Ball, Peter ^a,b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b By Oban ^*  (United Kingdom)

Author keywords

Acute exacerbations of chronic bronchitis; Community acquired pneumonia; Fluoroquinolones; Gram positive bacteria; Nosocomial pneumonia; Resistance; Respiratory tract infections

Indexed keywords

8 CHLORO 1 CYCLOPROPYL 7 (2,8 DIAZABICYCLO[4.3.0]NON 8 YL) 6 FLUORO 1,4 DIHYDRO 4 OXO 3 QUINOLINECARBOXYLIC ACID; AMOXICILLIN; CEFTRIAXONE; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLAVULANIC ACID; CLINAFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STEROID; TEMAFLOXACIN; THEOPHYLLINE; TROVAFLOXACIN;

AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; INFECTION CONTROL; LIVER FAILURE; LOWER RESPIRATORY TRACT INFECTION; NEUROLOGIC DISEASE; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SKIN DISEASE; TENDINITIS; TENDON RUPTURE;

EID: 1642520679     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2003.11.003     Document Type: Article

References (97)

1. Ball P. The quinolones: History and overview. In: Andriole VT, ed. The Quinolones. 3rd ed. San Diego, Calif: Academic Press; 2000:1-31.
2. Ball P, Fernald A, Tillotson G. Therapeutic advances of new fluoroquinolones. Exp Opin Invest Drugs. 1998;7:761-783.
3. Ball P. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect. J Antimicrob Chemother. 2000;45:557-559.
4. Ball P, Mandell L. Treatment of community-acquired respiratory tract infections. In: Hooper DC, Rubinstein E, eds. Quinolone Antimicrobial Agents. 3rd ed. Washington, DC: American Society of Microbiology Press; 2003:227-243.
5. Ball P. Future of the quinolones. Semin Respir Infect. 2001;16:215-224.
6. Ball P, Baquero F, Cars O, et al, for the Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother. 2002;49:31-40.
7. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2002;2:404-415.
8. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteraemia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35:556-564.
9. Mandell LA, Marrie TJ, Grossman RF, et al, for the Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000;31: 383-421.
10. Niedermann MS, Mandell LA, Anzueto A, et al, for the American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-1754.
11. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax. 2001;56(Suppl 4):S1-S64.
12. Yanagihara K, Kohno S, Matsusima T. Japanese guidelines for the management of community-acquired pneumonia. Int J Antimicrob Agents. 2001;18(Suppl 1):S45-S48.
13. Grossman RF. The role of fluoroquinolones in respiratory tract infections. J Antimicrob Chemother. 1997;40(Suppl A):59-62.
14. Banerjee D, Honeybourne D. The role of fluoroquinolones in chronic obstructive pulmonary disease. Curr Opin Infect Dis. 1999;12:543-547.
15. Ball P, Chodosh S, Grossman R, et al. Causes, epidemiology and treatment of bronchial infections. Infect Med. 2000;17:186-198.
16. Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: Results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother. 2001;48:659-665.
17. Critchley IA, Blosser-Middleton RS, Jones ME, et al. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. Int J Antimicrob Agents. 2002;20:100-107.
18. Chen DK, McGreer A, de Azavedo JC, Low DE, for the Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233-239.
19. Weiss K, Restieri C, Gauthier R, et al. A nosocomial outbreak of fluoroquinolone-resistant Streptococcus pneumoniae. Clin Infect Dis. 2001;33:517-522.
20. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: A case control study. Clin Infect Dis. 2001;32:701-707.
21. Garau J. Why do we need to eradicate pathogens in respiratory tract infections? Int J Infect Dis. 2003;7(Suppl 1):S005-S010.
22. Boswell FJ, Andrews JM, Jevons G, Wise R. Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother. 2002;50:495-502.
23. Madaras-Kelly KJ, Daniels C, Hegbloom M, Thompson M. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother. 2002;50:211-218.
24. Firsov AA, Zinner SH, Vostrov SN, et al. AUC/MIC relationships to different endpoints of the antimicrobial effect: Multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother. 2002;50:533-539.
25. Highet VS, Forrest A, Ballow CH, Schentag JJ. Antibiotic dosing issues in lower respiratory tract infection: Population-derived area under inhibitory curve is predictive of efficacy. J Antimicrob Chemother. 1999;43(Suppl A):55-63.
26. Preston SL, Drusano GL, Berman AL, et al. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother. 1998;42:1098-1104.
27. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials. JAMA. 1998;279:125-129.
28. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis. 2001;32(Suppl 1):S39-S46.
29. Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-683.
30. Andrews JM, Honeybourne D, Jevons G, et al. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1997;40:573-577.
31. Tavanic (levofloxacin) prescribing information [package insert]. Parsippany, NJ: Aventis; 2003.
32. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomised study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965-1972.
33. Norrby SR, Petermann W, Willcox PA, et al. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scand J Infect Dis. 1998;30:397-404.
34. Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: Integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther. 2001;23:425-439.
35. Carbon C, Ariza H, Rabie WJ, et al. Comparative study of levofloxacin and amoxicillin-clavulanic acid in adults with mild-to-moderate community-acquired pneumonia. Clin Microbiol Infect. 1999;5:724-732.
36. O'Hare M, Harding I. Levofloxacin therapy for community acquired pneumonia due to atypical and intracellular micro-organisms. J Antimicrob Chemother. 2001;47(Suppl S1):46. Abstract P-119.
37. Yu YL, Williams RR, Stout JE, et al. Levofloxacin is safe and effective in the management of community acquired pneumonia due to Legionella. J Antimicrob Chemother. 2001;47(Suppl S1):45. Abstract P-113.
38. Marrie TJ, Lau CY, Wheeler SL, et al, for the Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin (CAPITAL) Study Investigators. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA. 2000;283:749-755.
39. Marras TK, Lee-Pack L, Jamieson L, Chan CK. Effect of new guidelines and a respiratory quinolone on clinical outcomes in hospitalized patients with community-acquired pneumonia. J Antimicrob Chemother. 2001;47(Suppl S1):44-45. Abstract P-111.
40. Shah PM, Maesen FP, Dolmann A, et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: Results of a randomized, double-blind study. J Antimicrob Chemother. 1999;43:529-539.
41. Habib MP, Gentry LO, Rodriguez-Gomez G, et al. Multicenter randomised study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis. Infect Dis Clin Pract. 1998;7:101-109.
42. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;44:501-513.
43. Chodosh S, DeAbate CA, Haverstock D, et al, for the Bronchitis Study Group. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. Respir Med. 2000;94:18-27.
44. Ramirez A, Molina J, Dolmann A, et al. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results. J Respir Dis. 1999;20 (Suppl 11):S30-S39.
45. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5-and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents. 2001;18:503-512.
46. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: State of the art. Am J Med. 1991;91(Suppl 6A):87S-92S.
47. Anzueto A, Rizzo JA, Grossman RF. The infection-free interval: Its use in evaluating antimicrobial treatment of acute exacerbations of chronic bronchitis. Clin Infect Dis. 1999;28:1344-1345.
48. Halpern MT, Palmer CS, Zodet M, Kirsch J. Cost-effectiveness of gemifloxacin: Results from the GLOBE study. Am J Health Syst Pharm. 2002;59:1357-1365.
49. Jones P, Spencer S, for the Globe Study Group. Greater improvement in health status of smokers and ex-smokers treated for AECB with gemifloxacin versus clarithromycin: The Globe Study. J Antimicrob Chemother. 2001;47(Suppl Sl):43. Abstract P-106.
50. Anie K, Lowton K, Jones PW. Changes in health status following an acute exacerbation of chronic bronchitis. Eur Respir J. 1997;10(Suppl 25):148S. Abstract.
51. Spencer S, Anie K, Jones PW. Annual rate of health status decline in COPD patients is significantly related to frequency of acute exacerbations. Eur Respir J. 1999; 14(Suppl 30):19S. Abstract 232.
52. Destache CJ, Dewan N, O'Donohue WJ, et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1999;43(Suppl A):107-113.
53. Cipro (ciprofloxacin) [online]. West Haven, Conn: Bayer Corporation; 2003. Available at: http://www.ciprousa.com. Accessed October 31, 2003.
54. Avelox (moxifloxacin) [online]. West Haven, Conn: Bayer Corporation; 2003. Available at: http://www.aveloxusa.com. Accessed October 31, 2003.
55. Ball P, Mandell L, Niki Y, Tillotson G. Comparative tolerability of the newer fluoroquinolone antibacterials. Drug Saf. 1999;21:407-421.
56. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: A review focusing on newer agents. Clin Infect Dis. 1999;28:352-364.
57. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf. 1995;13:343-358.
58. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy [published correction appears in Drugs. 1994;48:132]. Drugs. 1994;47:677-700.
59. Iannini P, Kubin R, Reiter C. Over 10 million patient uses: An update on the safety profile of oral moxifloxacin. Poster presented at the 42nd Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, Calif; 2002. Poster L-374.
60. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxyquinolone. J Respir Dis. 1999;20(Suppl 11):S70-S76.
61. Domagala JM. Structure-activity and structure-side-effect relationships for the quinolone antibacterials [published correction appears in J Antimicrob Chemother. 1994; 34:851]. J Antimicrob Chemother. 1994;33:685-706.
62. Ferguson J. Fluoroquinolone photosensitization: A review of clinical and laboratory studies. Photochem Photobiol. 1995;62:954-958.
63. Wagai N, Yoshida M, Takayama S. Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice. Arzneimittelforschung. 1992;43:404-405.
64. Wagai N, Tawara K. Possible reasons for differences in phototoxic potential of 5 quinolone antibacterial agents: Generation of toxic oxygen. Free Radic Res Commun. 1992;17:387-398.
65. Marutani K, Matsumoto M, Otabe Y, et al. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob Agents Chemother. 1993;37:2217-2223.
66. Molnar J, Zhang F, Weiss J, et al. Diurnal pattern of QTc interval: How long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol. 1996;27:76-83.
67. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother. 2002;49:593-596.
68. Committee for Proprietary Medicinal Products. Points to Consider: The Assessment of the Potential for QT Interval Prolongation by Non-Cardiovascular Medicinal Products. London, United Kingdom: European Agency for Evaluation of Medicinal Products; 1997.
69. De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: An overview. Drug Saf. 2002;25:263-286.
70. Samaha FF. QTc interval prolongation and polymorphic ventricular tachycardia in association with levofloxacin. Am J Med. 1999;107:528-529. Letter.
71. Iannini PB, Circiumaru I. Gatifloxacin-induced QTc prolongation and ventricular tachycardia. Pharmacotherapy. 2001;21:361-362.
72. Iannini PB, Doddamani S, Byazrova E, et al. Risk of torsades de pointes with non-cardiac drugs. Prolongation of QT interval is probably a class effect of fluoroquinolones. BMJ. 2001;322:46-47.
73. Frothingham R. Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin. Pharmacotherapy. 2001;21:1468-1472.
74. Frothingham R. Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. Clin Infect Dis. 2002;35:896-897; author reply 897-898.
75. Owens RC Jr, Ambrose PG. Torsade de pointes associated with fluoroquinolones. Pharmacotherapy. 2002;22:663-668.
76. Bertino JS Jr, Owens RC Jr, Carnes TD, Iannini PB. Gatifloxacin- associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis. 2002;34:861-863.
77. Kahn JB. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect. J Antimicrob Chemother. 2000;46:847-848.
78. Tillotson GS, Ball P. Fluoroquinolone safety profiles - a review. Todays Ther Trends. 2002;20:419-435.
79. Shakibaei M, Pfister K, Schwabe R, et al. Ultrastructure of Achilles tendon of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother. 2000;44:261-266.
80. Royer RJ, Pierfitte C, Netter P. Features of tendon disorders with fluoroquinolones. Therapie. 1994;49:75-76.
81. van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: A study of 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum. 2001;45:235-239.
82. Fleisch F, Hartmann K, Kuhn M. Fluoroquinolone-induced tendinopathy: Also occurring with levofloxacin. Infection. 2000;28:256-257.
83. Casparian JM, Luchi M, Moffat RE, Hinthorn D. Quinolones and tendon ruptures. South Med J. 2000;93:488-491.
84. van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendonitis associated with fluoroquinolones. Br J Clin Pharmacol. 1999;48:433-437.
85. van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: Case control study. BMJ. 2002;324:1306-1307.
86. Pierfitte C, Royer RJ. Tendon disorders with fluoroquinolones. Therapie. 1996;51: 419-420.
87. Rothschild E, Saint-Pierre A. Tavanic - Important Pharmacovigilance Information Concerning Tavanic (Levofloxacin) [in French]. Paris, France: Division of Pharmacovigilance, Dept of Health; December 17, 2001.
88. Blum A. Ofloxacin-induced severe hepatitis. South Med J. 1991;84:1158. Letter.
89. Nicholson SC, Webb CD, Moellering RC Jr. Antimicrobial-associated acute hepatitis. Pharmacotherapy. 2002;22:794-796.
90. Karim A, Ahmed S, Rossoff LJ, et al. Possible levofloxacin-induced acute hepatocellular injury in a patient with chronic obstructive lung disease. Clin Infect Dis. 2001; 33:2088-2090.
91. Chen HJ, Block KJ, Maclean JA. Acute eosinophilic hepatitis from trovafloxacin. N Engl J Med. 2000;342:359-360.
92. Suchard J. Review: Wherefore withdrawal? The science behind recent drug withdrawals and warnings. Int J Med Toxicol. 2001;4:15. Available at: http://www.ijmt.net/4_2/ 4_2_15.htm. Accessed November 5, 2003.
93. European Agency for the Evaluation of Medicinal Products. Public Statement on Trovan/Trovan IV/Turvel/Turvel IV (Trovafloxacin/Alatrofloxacin). Recommendation to Suspend the Marketing Authorisation in the European Union. London, United Kingdom: European Agency for the Evaluation of Medicinal Products; June 15, 1999. Publication EMEA/18046/99.
94. Blum MD, Graham DJ, McCloskey CA. Temafloxacin syndrome: A review of 95 cases. Clin Infect Dis. 1994;18:946-950.
95. Henann NE, Zambie MF. Gatifloxacin-associated acute hepatitis. Pharmacotherapy. 2001;21:1579-1582.
96. Yagawa K. Latest industry information on the safety profile of levofloxacin in Japan. Chemotherapy. 2001;47(Suppl 3):38-43.
97. Echols RM, Oliver MK. Ciprofloxacin safety relative to temafloxacin and lomefloxacin. In: Einhorn J, Nord CE, Norrby SR, eds. Recent Advances in Chemotherapy: Proceedings of the 18th International Congress of Chemotherapy. Washington, DC: American Society of Microbiology; 1994:349-350.